CA2910398A1 - Methods, systems, and compositions for promoting bone growth - Google Patents
Methods, systems, and compositions for promoting bone growthInfo
- Publication number
- CA2910398A1 CA2910398A1 CA2910398A CA2910398A CA2910398A1 CA 2910398 A1 CA2910398 A1 CA 2910398A1 CA 2910398 A CA2910398 A CA 2910398A CA 2910398 A CA2910398 A CA 2910398A CA 2910398 A1 CA2910398 A1 CA 2910398A1
- Authority
- CA
- Canada
- Prior art keywords
- oxopyrrolidin
- hydroxy
- methyl
- difluoro
- thiophene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/365—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361856370P | 2013-07-19 | 2013-07-19 | |
US61/856,370 | 2013-07-19 | ||
US201461928843P | 2014-01-17 | 2014-01-17 | |
US61/928,843 | 2014-01-17 | ||
PCT/US2014/047138 WO2015009991A2 (en) | 2013-07-19 | 2014-07-18 | Methods, systems, and compositions for promoting bone growth |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2910398A1 true CA2910398A1 (en) | 2015-01-22 |
Family
ID=51352759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2910398A Abandoned CA2910398A1 (en) | 2013-07-19 | 2014-07-18 | Methods, systems, and compositions for promoting bone growth |
Country Status (9)
Country | Link |
---|---|
US (1) | US10729810B2 (zh) |
EP (1) | EP3021879A2 (zh) |
JP (1) | JP2016527006A (zh) |
KR (1) | KR20160048054A (zh) |
CN (1) | CN105392505A (zh) |
AU (1) | AU2014290512A1 (zh) |
CA (1) | CA2910398A1 (zh) |
PH (1) | PH12015502854A1 (zh) |
WO (1) | WO2015009991A2 (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2879506C (en) | 2012-07-19 | 2020-10-27 | Cayman Chemical Company, Inc. | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions |
WO2015196020A1 (en) * | 2014-06-20 | 2015-12-23 | 3-D Matrix, Ltd. | Materials and methods for filling dental bone voids |
CN107427526B (zh) | 2014-12-09 | 2021-08-03 | 华沙整形外科股份有限公司 | 涉及甾醇的化合物和方法 |
CN105012995B (zh) * | 2015-06-04 | 2018-03-09 | 武汉维斯第医用科技股份有限公司 | 一种含促骨愈合药物的胶原蛋白海绵及其制备方法 |
WO2016196925A1 (en) * | 2015-06-04 | 2016-12-08 | The Regents Of The University Of California | Composition for bone and methods of making and using the same |
US9878070B2 (en) | 2015-06-17 | 2018-01-30 | Warsaw Orthopedic, Inc. | Malleable implants including an oxysterol and methods of use |
US9987289B2 (en) | 2015-07-10 | 2018-06-05 | Warsaw Orthopedic, Inc. | Slow release oxysterols and methods of use |
US10632230B2 (en) | 2015-07-10 | 2020-04-28 | Warsaw Orthopedic, Inc. | Implants having a high drug load of an oxysterol and methods of use |
US9877836B2 (en) | 2015-07-10 | 2018-01-30 | Warsaw Orthopedic, Inc. | Compression resistant implants including an oxysterol and methods of use |
HU231033B1 (hu) | 2016-03-22 | 2019-12-30 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Eljárás 3-as kötést tartalmazó optikailag aktív karbonsavak, karbonsav sók és karbonsav származékok előállítására |
CN105816919B (zh) * | 2016-05-23 | 2019-06-11 | 烟台正海生物科技股份有限公司 | 一种含有天然纳米羟基磷灰石的复合材料及其制备方法 |
EP3526242A1 (en) | 2016-10-12 | 2019-08-21 | University of Copenhagen | Peptide dual agonists of gipr and glp2r |
US11384114B2 (en) | 2016-12-09 | 2022-07-12 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
CN106699604B (zh) * | 2017-01-09 | 2019-01-01 | 四川同晟生物医药有限公司 | 一种沙库比曲及其中间体的制备方法 |
US10434106B2 (en) | 2017-05-19 | 2019-10-08 | Warsaw Orthopedic, Inc. | Oxysterol-statin compounds for bone growth |
US11464888B2 (en) | 2017-06-12 | 2022-10-11 | Warsaw Orthopedic, Inc. | Moldable formulations containing an oxysterol in an acellular tissue matrix |
CN108822090B (zh) * | 2018-08-17 | 2020-11-17 | 杭州乐敦科技有限公司 | 一种他汀类药物中间体的制备方法 |
WO2020051646A1 (en) * | 2018-09-14 | 2020-03-19 | Orthocell Limited | Artificial periosteum |
WO2020163290A1 (en) * | 2019-02-04 | 2020-08-13 | Emory University | Sclerostin inhibitors that promote bone morphogenetic protein expression |
CN110590351B (zh) * | 2019-08-23 | 2021-05-25 | 中国科学院上海硅酸盐研究所 | 一种黑色生物活性陶瓷粉体及其应用 |
CN114014647B (zh) * | 2021-10-21 | 2022-12-16 | 华南理工大学 | 一种硅酸锌复合磷酸三钙陶瓷支架及其制备方法与应用 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
DE2517771A1 (de) | 1975-04-18 | 1976-10-28 | Schering Ag | Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung |
CA1085859A (en) | 1975-06-27 | 1980-09-16 | Wilhelm Bartmann | Pyrrolidones and process for their manufacture |
DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
US4268522A (en) | 1976-06-14 | 1981-05-19 | Pfizer Inc. | 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof |
US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
US4456613A (en) | 1982-12-27 | 1984-06-26 | E. I. Du Pont De Nemours And Company | 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof |
US7208179B1 (en) | 1990-11-27 | 2007-04-24 | The American National Red Cross | Methods for treating disease and forming a supplemented fibrin matrix |
CA2093836A1 (en) | 1992-04-24 | 1993-10-25 | Wayne Gombotz | Biodegradable tgf-.beta. delivery system for bone regeneration |
JP3388867B2 (ja) | 1994-03-31 | 2003-03-24 | 株式会社東芝 | 宛名領域検出装置および宛名領域検出方法 |
WO1996014335A1 (en) | 1994-11-07 | 1996-05-17 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services | Cartilage-derived morphogenetic proteins |
US7517539B1 (en) | 1996-10-16 | 2009-04-14 | Etex Corporation | Method of preparing a poorly crystalline calcium phosphate and methods of its use |
ZA984040B (en) | 1997-05-15 | 1998-11-20 | Ono Pharmaceutical Co | Benzenesulfonamide compounds |
US6043275A (en) | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
AU1293101A (en) | 1999-12-22 | 2001-07-03 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
US20010056060A1 (en) | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
WO2002024647A1 (fr) | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
CA2429850C (en) * | 2000-11-27 | 2008-12-30 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
BR0211167A (pt) | 2001-07-16 | 2004-08-10 | Hoffmann La Roche | Derivados de 2-pirrolidona como agonistas de prostanóides |
KR20040015364A (ko) | 2001-07-16 | 2004-02-18 | 에프. 호프만-라 로슈 아게 | Ep4 수용체 작용물질로서의 프로스타글란딘 유사체 |
MXPA04000757A (es) | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
ATE391503T1 (de) | 2001-10-23 | 2008-04-15 | Serono Lab | Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren |
EP1453503A4 (en) | 2001-12-03 | 2005-03-30 | Merck & Co Inc | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS |
WO2003047513A2 (en) | 2001-12-03 | 2003-06-12 | Merck & Co., Inc. | Method for treating ocular hypertension |
JP4547912B2 (ja) | 2002-03-05 | 2010-09-22 | 小野薬品工業株式会社 | 8−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤 |
JP2005531516A (ja) | 2002-03-18 | 2005-10-20 | ファイザー・プロダクツ・インク | 選択的ep4受容体アゴニストによる治療方法 |
WO2003077908A1 (en) | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
US7326426B2 (en) | 2002-03-29 | 2008-02-05 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable liquid polymers |
US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
EP1556347A4 (en) | 2002-06-10 | 2006-08-09 | Applied Research Systems | GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE |
JP2006505572A (ja) | 2002-10-25 | 2006-02-16 | メルク フロスト カナダ アンド カンパニー | Ep4受容体アゴニストとしての2−ピロリドン |
WO2004065365A1 (ja) | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | 8−アザプロスタグランジン誘導体およびその医薬用途 |
JP4662926B2 (ja) | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
US7163920B2 (en) | 2003-09-30 | 2007-01-16 | Ethicon, Inc. | Peptide with osteogenic activity |
BRPI0417621A (pt) | 2003-12-17 | 2007-04-10 | Pfizer Prod Inc | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea |
US7169807B2 (en) | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
WO2006016695A1 (ja) | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤 |
JP4888775B2 (ja) | 2004-08-10 | 2012-02-29 | 小野薬品工業株式会社 | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
US20060039949A1 (en) | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
US20060057184A1 (en) | 2004-09-16 | 2006-03-16 | Nycz Jeffrey H | Process to treat avascular necrosis (AVN) with osteoinductive materials |
US7621963B2 (en) * | 2005-04-13 | 2009-11-24 | Ebi, Llc | Composite bone graft material |
CN101247789B (zh) | 2005-05-27 | 2012-06-27 | 罗耶化学医药公司 | 可生物再吸收聚合物基质及其制造和使用方法 |
WO2007030616A2 (en) | 2005-09-09 | 2007-03-15 | Wright Medical Technology, Inc. | Composite bone graft substitute cement and articles produced therefrom |
KR20060013354A (ko) | 2005-12-09 | 2006-02-09 | (주)코리아 본 뱅크 | 인산칼슘계 시멘트 첨가에 의해 개질된 탈회골 기질의 개발 |
US20070232660A1 (en) | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
AU2008246579A1 (en) | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
US7998998B2 (en) | 2007-10-23 | 2011-08-16 | Allergan, Inc. | Therapeutic substituted lactams |
US20090112332A1 (en) | 2007-10-31 | 2009-04-30 | Alexis Paul Shelokov | Bone graft and bone graft substitutes with antibiotics for sustained, localized release of antibiotics for reducing postoperative surgical wound infection in spinal and other bone surgery |
WO2011127149A1 (en) | 2010-04-06 | 2011-10-13 | University Of Utah Research Foundation | Controlled release combination biomaterials |
US8685432B2 (en) | 2008-03-25 | 2014-04-01 | University Of Utah Research Foundation | Controlled release tissue graft combination biomaterials |
CN102065914A (zh) * | 2008-04-15 | 2011-05-18 | 埃泰克斯公司 | 使用磷酸钙组合的骨接合剂的脊椎骨最小侵入性治疗(mitv) |
WO2010011599A2 (en) | 2008-07-22 | 2010-01-28 | Osteogenex Inc. | Pimethixene derivatives for promoting bone growth |
US20100055183A1 (en) | 2008-08-28 | 2010-03-04 | Osteogenex Inc. | Trimeprazine and ethopropazine derivatives for promoting bone growth |
DE102008047405A1 (de) * | 2008-09-11 | 2010-04-15 | Technische Universität Dresden | Kompositmaterialien aus einer mit Silikat und Calciumphosphatphasen mineralisierten Kollagenmatrix, Verfahren zu deren Herstellung und deren Verwendung |
JP2010273847A (ja) * | 2009-05-28 | 2010-12-09 | Tokyo Institute Of Technology | 高密度多孔質複合体 |
WO2011003058A1 (en) | 2009-07-03 | 2011-01-06 | Concert Pharmaceuticals, Inc. | Prostacyclin derivatives |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
EP2638008B1 (en) | 2010-11-10 | 2015-07-01 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
CN103313733A (zh) * | 2010-11-15 | 2013-09-18 | 捷迈整形外科生物材料有限公司 | 骨空隙填充剂 |
US20120283293A1 (en) | 2011-05-06 | 2012-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation |
WO2013018837A1 (ja) | 2011-08-02 | 2013-02-07 | 小野薬品工業株式会社 | 左室拡張機能改善剤 |
CA2879506C (en) | 2012-07-19 | 2020-10-27 | Cayman Chemical Company, Inc. | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
EA201591793A1 (ru) | 2013-03-15 | 2016-01-29 | Кайман Кемикал Компани, Инк. | Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний |
-
2014
- 2014-07-18 EP EP14750837.8A patent/EP3021879A2/en not_active Withdrawn
- 2014-07-18 AU AU2014290512A patent/AU2014290512A1/en not_active Abandoned
- 2014-07-18 US US14/905,663 patent/US10729810B2/en active Active
- 2014-07-18 CN CN201480039423.2A patent/CN105392505A/zh active Pending
- 2014-07-18 CA CA2910398A patent/CA2910398A1/en not_active Abandoned
- 2014-07-18 KR KR1020167001059A patent/KR20160048054A/ko not_active Application Discontinuation
- 2014-07-18 JP JP2016527117A patent/JP2016527006A/ja active Pending
- 2014-07-18 WO PCT/US2014/047138 patent/WO2015009991A2/en active Application Filing
-
2015
- 2015-12-22 PH PH12015502854A patent/PH12015502854A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015009991A2 (en) | 2015-01-22 |
PH12015502854A1 (en) | 2016-03-28 |
JP2016527006A (ja) | 2016-09-08 |
AU2014290512A1 (en) | 2015-11-12 |
WO2015009991A3 (en) | 2015-07-16 |
US20160158413A1 (en) | 2016-06-09 |
KR20160048054A (ko) | 2016-05-03 |
US10729810B2 (en) | 2020-08-04 |
EP3021879A2 (en) | 2016-05-25 |
WO2015009991A8 (en) | 2015-12-17 |
CN105392505A (zh) | 2016-03-09 |
AU2014290512A8 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10729810B2 (en) | Methods, systems, and compositions for promoting bone growth | |
AU2017200044B2 (en) | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated disease and conditions | |
JP2017186356A (ja) | Ep4媒介性の疾病及び病態の治療に使用するためのep4受容体選択性アゴニストとしてのラクタム化合物 | |
WO2014144610A1 (en) | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20151023 |
|
FZDE | Discontinued |
Effective date: 20190219 |